It is made available under a CC-BY 4.0 International license .

The unmutated common ancestor of Gp41 conformational epitope targeting variable heavy chain 1-02 utilizing antibodies maintains antibody dependent cell cytotoxicity.

Brian H. Wrotniak¹, Meghan Garrett², Sarah Baron¹, Hakimuddin Sojar¹, Alyssa Shon³, Elizabeth Asiago-Reddy⁴, Jessica Yager⁵, Spyros Kalams⁶, Michael Croix¹, and Mark D Hicar^{1.} 1 Department of Pediatrics, University at Buffalo, Buffalo, New York, USA

2 Human Biology Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA

3 Department of Medicine, University at Buffalo, Buffalo, NY, USA

4 Department of Medicine, SUNY Upstate, Syracuse, NY, USA

5 Department of Medicine, SUNY Downstate, New York City, NY, USA

6 Department of Internal Medicine, Vanderbilt University, Nashville, TN, USA

Corresponding author:

Mark Daniel Hicar. ORCID: 0000-0002-1768-5419 University at Buffalo 6072 UB CTRC 875 Ellicott Street Buffalo, NY 14203 USA Phone: (716) 888-4872 Fax: (716) 888-3804 Email: markhica@buffalo.edu Alt email: markhicar@gmail.com

It is made available under a CC-BY 4.0 International license .

1 Abstract:

In studies on monoclonal Abs (mAbs) from long-term non-progressors (LTNPs), our
laboratory has previously described highly mutated Abs against a complex conformational
epitope with contributions from both gp41 heptad repeat regions. Despite using the VH1-02
gene segment, known to contribute to some of the broadest neutralizing Abs against HIV,
members of these Abs, termed group 76C Abs, did not exhibit broad neutralization.

7 Because of the excessive mutations and use of VH1-02, our goal was to characterize 8 the non-neutralizing functions of Abs of group 76C, to assess targeting of the epitope in 9 various clinical presentations, and to assess the development of these Abs by comparison to 10 their predicted common ancestor. Serum competition assays showed group 76C Abs were 11 enriched in LTNPs, in comparison to VRC-01. Specific group 76C clones 6F5 and 6F11, 12 expressed as recombinant Abs, both have robust ADCC activity, despite their sequence 13 disparity. Sequence analysis predicted the common ancestor of this clonal group would utilize 14 the germline non-mutated variable gene. We produced a recombinant ancestor Ab (76Canc) 15 with a heavy chain utilizing the germline variable gene sequence paired to the 6F5 light chain. 16 Competition with group 76C recombinant Ab 6F5 confirms 76Canc binds HIV envelope 17 constructs near the original group C epitope. 76Canc demonstrates comparable ADCC to 6F5 18 and 6F11 when targeting both clade B and C HIV constructs. The functional capability of Abs 19 utilizing germline VH1-02 has implications for disease control and vaccine development.

- 20
- 21

It is made available under a CC-BY 4.0 International license .

22 Introduction:

23 The creation of a successful HIV vaccine continues to be a public health priority. A large 24 effort has been focused on discovery and characterization of broadly neutralizing Abs (bnAbs). 25 Whether similar bnAbs can be induced from stimulation of native B cells during immunization 26 has been a challenge in HIV vaccine design. We previously used HIV virus-like particles to 27 bind B cells from long-term non-progressor (LTNP) subjects. From these B cells, a number of 28 mAbs were cloned and showed an extreme number of mutations, similar to many of the known 29 bnAbs. When expressed as recombinant full-length Abs, some showed specificity or higher 30 affinity for trimerized envelope and virus-like particles, which we termed quaternary-targeting 31 Abs (QtAbs) (Hicar, Chen, Sulli, et al., 2016). Despite the highly mutated nature of these Abs, 32 they are generally non-neutralizing Abs (nnAbs) (Hicar, Chen, Kalams, et al., 2016). 33 Recent studies have shown that a number of these highly mutated QtAbs have the 34 capacity to mediate Ab dependent cell cytotoxicity (ADCC) (Sojar et al., 2019). ADCC was 35 implicated in the RV144 vaccine trial success (Haynes et al., 2012). The Fc portion of Abs.

which ADCC is dependent on, is crucial in protection (Hessell et al., 2007). Passive Ab
infusions of both neutralizing (Hessell et al., 2009; Parren et al., 1995; Parren et al., 1996) and
non-neutralizing Abs protect macaques in a SHIV mucosal challenge model (Santra et al.,
2015). NnAbs targeting structural epitopes in gp41 have shown ADCC function and limiting of
cell-to-cell spread of infection (Bonsignori et al., 2012). Other nnAbs targeting this same gp41
epitope, such as F240 (Burton et al., 2011) and 7B2 (Santra et al., 2015), can protect
macagues during SHIV vaginal challenge. ADCC-mediating Abs from an HIV-1 vaccine

43 efficacy trial target multiple epitopes and preferentially use the VH1 gene family (Bonsignori et

44 al., 2012). ADCC activity of Abs using VH1 genes correlated with the degree of somatic

It is made available under a CC-BY 4.0 International license .

45 mutation. ADCC activity has been associated with control of HIV in the past (Lambotte et al.,
2009) and more recent polyfunctionality, including ADCC, of Abs has been shown to correlate
47 with control (Das et al., 2020).

48 We have previously mapped another highly mutated (83% homologous to predicted 49 heavy chain germline) QtAb, mAb 76-Q13-6F5 (6F5), to a novel structural epitope. The 6F5 50 epitope encompasses areas in both heptad repeats of gp41, mapping by alanine scanning 51 mutagenesis to amino acids R557, E654 and E657 of reference sequence HXB2 (Hicar, Chen, 52 Sulli, et al., 2016). Since alanine scanning mutagenesis showed widely separated amino acids 53 as potentially involved, this suggested a structural epitope that is available on post-fusion 54 forms. From these studies, Abs from other genetically related groups (Q7 and Q11) also 55 showed that E657 was critical for binding using alanine scanning mutagenesis. On sequence 56 analysis, 10076-Q7-6F11 (6F11), 10076-Q7-7C6 (7C6), 10076-Q11-4E4 (4E4) and 6F5 had 57 the same CDR3 length and, the same predicted germline sequences for both heavy (VH1-02) 58 and light chains (VK1-39), but had < 90% of shared nucleotide sequence (Hicar, Chen, Sulli, et 59 al., 2016). 6F11, 7C6, and 4E4 also competed with 6F5 binding to HIV envelope trimers, so 60 these were classified into a single epitope group (group 76C). Despite the low homology, these 61 similarities and the similar epitope mapping implied these were once distantly related to a 62 single B cell lineage.

Since group 76C Abs bind trimers and interfere with the function of fusion inhibitors
(Smith et al., 2018), the targeted epitope is at least partially available in the pre-fusion state.
Since fusion of the viral membrane to the target cell depends on heptad repeat regions
associating and forming a six-helix-bundle (6HB) post-fusion, these group 76C Abs allow us to
explore development of functional targeting to this complex gp41 epitope. Because of the wide

It is made available under a CC-BY 4.0 International license .

disparity in the mature group 76C Abs, the predicted common ancestor of these Abs would

69 utilize germline VH1-02. From exploring the derivation and possible cross-reactivity of such

Abs, we discovered that the germline VH1-02 gene can support ADCC functional activity.

71

72 Materials & Methods:

73 Clinical Samples: LTNP were defined as those individuals who maintained CD4 counts > 300/mm³ for minimally 7 years without therapy post-diagnosis. LTNP samples were collected 74 75 from State University of New York clinical sites and shared as codified samples with 76 associated clinical information under the UB IRB STUDY00000359. Biobanked samples from 77 controls and additional LTNP samples accessed through the Biorepository at the University of 78 Washington, through collaboration with receipt of deidentified samples from Vanderbilt 79 University. Controls requested from the biorepository were infected for over 7 years and did 80 not continually maintain CD4s and/or went on therapy prior to the seventh year of infection. 81

82 Statistical analysis: For the serum comparison of LTNP to other HIV infected, power 83 calculations for 80% power with alpha of 0.05 based on means of 50% of inhibition versus 60% 84 inhibition with relatively wide variance (10%) suggested we would need minimally 16 members 85 in each group. The levels of binding antibodies in LTNPs were compared to serum from a group 86 of HIV infected controls with comparable viral loads using Mann–Whitney U tests (two-tailed and 87 alpha set at 0.05). Analyses were conducted using SYSTAT software version 13 (SYSTAT 88 Software, 2004), with statistical tests applied as described in the figure legends. Graphpad 89 Prism 9 was used for graphical representation of data was, with means and standard 90 deviations shown unless otherwise noted.

It is made available under a CC-BY 4.0 International license .

91

92 76 Group C antibodies: During the initial characterization of recombinant Ab binding, 93 the mAb 6F5 competed with three other Abs:76-Q7-6F11 (6F11), 76-Q7-7C6 (7C6), and 76-94 Q11-4E4 (4E4) (Hicar, Chen, Sulli, et al., 2016). These Abs shared the same predicted 95 variable chain sequences (VH1-2, VK1-39) and had the same CDR lengths, consistent with a 96 distal clonal relationship. Their original clone names contain the subject (76 for 10076),-97 Qxx(for guaternary targeting clonal group), and then the specific Ab reference. These were 98 originally assigned to different groups (Q7, Q11, and Q13) using the definition of clonality of 99 having same heavy chain CDR3 region length, >90% CDR3 nucleotide identity, and having 100 overall amino acid sequence homology of > 90%. Two other heavy chains (76-Q2-1F7 and 76-101 Q2-1B1) had similar variable gene usage and structure, but did not have light chain pairs 102 isolated so were not characterized as recombinant Abs. Within this manuscript, these Abs are 103 referred to by their shortened specific clonal names (*i.e.* 6F5) (Hicar, Chen, Kalams, et al., 104 2016).

105

106 **Full-length Ab expression:** After cloning into an expression vector, heavy and light 107 chain Ab plasmid DNA were amplified using the Pure Yield Plasmid Maxiprep System 108 (Promega #A2392) following the manufacturer's instructions. Plasmids were then co-109 transfected into Free Style 293-F cells. Briefly, 50 µg of DNA per 100 ml of culture was mixed 110 with 3 ml of Opti-MEM I Reduced Serum Medium (Thermo Scientific #31985062) and sterile 111 filtered. Next, 100 ul of 1mg/ml polyethylenimine (PEI) per 100 ml of culture was added to 3 ml 112 of Opti-MEM I reduced Serum Medium and sterile filtered. The DNA and PEI solutions were 113 then mixed dropwise, vortexed, and incubated for 12 minutes at room temperature. The

It is made available under a CC-BY 4.0 International license .

114	mixture was added to 100 ml of Free Style 293-F cells seeded in Free Style 293 Expression
115	Medium (Thermo Scientific #12338018) at a density of 1x10 ⁶ cells/ml and left to incubate for
116	six days at 37°C 8% CO ₂ on a shaker with 130 rpm speed. On the 6^{th} day of transfection,
117	culture supernatants were collected and cleared by centrifugation at 3000 x g for 15 minutes at
118	4° C and then filtered through a 0.2 μ m filter. Following filtration, immunoglobulins were purified
119	using a 5 ml HiTrap Protein G column (GE Healthcare 17-0404-01) on an AKTA FPLC (GE
120	Healthcare, Piscataway NJ). The IgG fraction was recovered from the column by elution with
121	glycine buffer (100 mM, pH 2.5). The fractions containing IgG were pooled and exchanged with
122	1x PBS (pH 7.4) via 3 washes using Amicon Ultra-2mL Ultracel-10kDa cutoff (Millipore Corp.,
123	Bedford, MA). A Tris-HCI neutralization step was avoided as it may interfere with later
124	biotinylation steps. Ab concentrations were measured on a Nano Drop Lite Spectrophotometer
125	(Thermo Scientific).

126

127 Ab binding ELISAs: Immulon 2-HB plates were coated with respective antigen in 0.1 128 mM sodium bicarbonate buffer pH 8.4 overnight at 4°C.The next day plates were blocked with 129 10% Fetal bovine serum (FBS) in PBS for 2 hrs at 4°C. After removing blocking buffer, 100 ul 130 of respective Ab diluted in 10% FBS was added and incubated at 37°C for 1 hr. After 1 hr 131 plates were washed with washing buffer (PBS containing 0.1% Tween 20) three times. After 132 washing 100 ul of HRP conjugated secondary Ab in blocking buffer was added and incubated 133 at room temperature for 1 hr. Plates were washed three times with washing buffer and 50ul 134 Ultra-TMB (Thermo Scientific) substrate was added to each well and the reaction was stopped 135 by adding 50ul of 2N sulfuric acid. Absorbance was measured at 450nM optical density within 136 30 min.

It is made available under a CC-BY 4.0 International license .

137

138 Ab biotinylation competition ELISAs: Ab biotinylation was performed as previously 139 described (Hicar, Chen, Sulli, et al., 2016). First, 100-200 µl of 3 mg/ml Abs were equilibrated 140 in carbonate buffer (pH 9.3) using a 10k or 50k cutoff Amicon Ultra-4 Centrifugal Filter Unit 141 (Millipore Corp., Billerica, MA) per the manufacturer's instructions. Ab concentrations were 142 measured using a Nanodrop spectrophotometer (Thermo Scientific, Grand Island, NY). 143 Sulfosuccinimide biotin (Sigma-Aldrich, St. Louis, MO) was added at a 30-fold molar excess 144 over the concentration of Ab (approximately 90 µg per mg of Ab). This solution was mixed and 145 incubated for 30 minutes with gentle shaking at room temperature. Tris-HCI (pH 7.5) was 146 added up to 10% by volume to bind residual biotin molecules. The biotinylated Ab was 147 separated from residual biotin complexes and equilibrated with PBS (pH 7.4) using a G-25 148 Sephadex Nap-5 (GE Healthcare, Piscataway NJ) column per the manufacturer's protocol. 149 Biotinylated Abs were competed with a panel of known unlabeled HIV-specific Abs, as listed in 150 the results section. ELISAs were performed similar to previous description, with streptavidin-151 HRP (Southern Biotech, Birmingham, AI) conjugated secondary Ab reagent for detection of 152 binding.

153

Western blot analysis: After running on SDS-PAGE, proteins were transferred onto blotting membrane using lblot dry blotting system (Thermo Fisher Scientific) according to the manufacturer's instructions. After transfer, the blot was blocked for 1 hr at room temperature. After rinsing, primary Ab was diluted in 10% FBS was added and incubated overnight at 4°C. Blot was washed (3 x 10 minutes) with gentle agitation. Secondary Ab (Alkaline phosphatase conjugated anti-human IgG, Southern Biotech, Birmingham, AL) was added in wash buffer and

It is made available under a CC-BY 4.0 International license .

incubated for 1 hour at room temperature with gentle agitation. Blot was then washed
 5x5minutes, three times in PBST and twice in PBS. Bands were visualized with Alkaline
 phosphate substrate NBT/BCIP (Thermo Scientific, Grand Island, NY).

163

164 Six-helix-bundle (6HB) formation and binding: Protocol followed previous 165 publication (Liu, Zhao, & Jiang, 2003). Peptide N36 in PBS was incubated with C34 at 37°C for 166 1 hr. The mixture was added to 96- well plates which were precoated with NC-1 IgG (1ug/ml) 167 purified from mouse antisera directed against the gp41 6HB. The plate was incubated for 2 hr 168 at room temperature. Plate was extensively washed with washing buffer containing Tween-20. 169 Then primary Abs were added at various dilutions and incubated at 37°C for 1 hr. The plate 170 was washed extensively with washing buffer and secondary HRP-conjugated anti human IgG 171 (H+L) at 1:2000 dilution was added in each well and incubated at room temperature for 1 hr. 172 The plate was washed and TMB substrate was added for color development and the reaction 173 was stopped using 2N sulfuric acid. Human anti-HIV-1 gp41 Ab HK20 was used as a control 174 (Creative Biolabs, Shirley, NY).

175

Ab dependent cellular cytotoxicity assay: Rapid and fluorometric ADCC (RFADCC) assay was performed as described previously (Milligan, Richardson, John-Stewart, Nduati, & Overbaugh, 2015; Williams et al., 2015). Briefly, CEM-NKr target cells were double stained with PKH (a membrane stain) and CFSE (a cytosolic stain) and coated with 50ug/ml ZA 1197 MNgp41 (NIH AIDS Reagent Program). The coated target cells (5000 cells/well) were incubated with the Ab for 10 minutes to allow binding of the Ab to gp41. Next, effector cells (HIV-negative donor PBMCs) were added at an effector target ratio of 50:1. The mixture was

It is made available under a CC-BY 4.0 International license .

- incubated for 4 hours at 37^oC. After the incubation, the cells were fixed in 1%
- 184 paraformaldehyde in PBS. When ADCC occurred, the target cell membrane is permeabilized
- 185 leading to the loss of CFSE and retention of PKH. ADCC was measured by flow cytometry as
- 186 the percentage of PE (+) CFSE (-) cells among all PE (+) cells with background (average
- 187 ADCC mediated against uncoated target cells) subtracted. Background was set to 3-5%.
- 188 Influenza Ab F16V3 (500 ng/uL) was included as a negative control and results are normalized
- to HIV immunoglobulin (HIVIG, 500 ng/uL).
- 190
- 191
- 192


It is made available under a CC-BY 4.0 International license .

193 **Results**:

194 Enrichment for Antibodies binding against 76C epitope in Long-term non-progressors

195 Recent studies support that specific polyfunctional Abs may influence disease 196 progression (Das et al., 2020). Prior studies that showed that ADCC was globally higher in 197 controllers, also studied specific epitope targeting by serum competition with biotinylated Abs. 198 No differences in Abs targeting the CD4 binding site or other epitopes associated with 199 neutralization were shown between viremic individuals and viral controllers (Lambotte et al., 200 2009). The 76C group Abs target a previously unassessed conformational epitope in gp41. We 201 used 6F11 as the representative biotinylated Ab since it had a higher affinity for HIV BaL 202 foldon trimers (Hicar, Chen, Kalams, et al., 2016), the target we chose for this assay. Samples 203 were obtained from recruitment and biobank access from 35 LTNP individuals (Minimally 7 204 years off therapy with stable CD4 counts), and 58 HIV infected individuals with comparable

It is made available under a CC-BY 4.0 International license .



It is made available under a CC-BY 4.0 International license .

215 Functional activity

- 216 In prior studies, group 76C Abs did not neutralize various tiers of HIV strains (Hicar,
 - 217 Chen, Kalams, et al., 2016). We have recently shown that members of this group 76C can




Figure 2: Antibody dependent cell cytotoxicity of group 76C Abs 6F5 and 6F11. Percent killing of cells coated with MN gp41 and ZA 1197 gp41 mediated by group 76C Abs 6F11 and 6F5 are shown. Results are compared to negative control bnAb 2G12, anti-influenza Ab F16V3 and positive controls HIVIG, Ab QA255.006 (gp41 Ab with ADCC), and the structural targeting Ab 76A-2C6. Results shown represent a single experiment (with two replicates) for group MN gp41 and the combined data of two experiments using two different donors for ZA1197 gp41.

interfere in certain fusion interference assays implying that a portion of this epitope is available prefusion (Smith et al., 2018). In the original studies that identified 6F5, the clade B virus-like

- 229 particle also identified the Ab 76A-2C6 (classified as group A due to targeting of a separate
- 230 epitope). 76A-2C6 targets a complex conformational epitope, recognizes multiple clades, and
- was shown to have robust ADCC activity using both clade B and clade C constructs (Sojar et
- al., 2019). So, we chose to test for ADCC activity in these group C Abs using clade B MN and
- clade C ZA1197 gp41 constructs. Group 76C members 6F5 and 6F11 both showed
- comparable ADCC activity to 76A-2C6, QA255.006 and HIVIG (**Figure 2**).
- 235
- 236
- 237 Sequence, creation of group 76C ancestor

It is made available under a CC-BY 4.0 International license .

238	6F5 binds a conformational epitope on gp41. On analysis for common shared
239	mutations, besides those noted within the CDR3 regions, there were no shared mutations from
240	germline across all six putative members in heavy chain or of the four that had cloned light
241	chains (Figure 3). This surprisingly suggested a propensity for germline variable chain binding
242	to target this antigenic site. Notably 6F11 and 7C6 had the exact same CDR3 segment in both
243	the heavy and light chains. 4E4 shared rare mutations with all 76C members and was the least
244	mutated (87.5% homology to predicted germline) of the 76C members. Thus, we created an
245	ancestor Ab (76Canc) by expressing the 6F5 light chain with a heavy chain construct utilizing
246	the germline VH1-02 sequence (through framework 3) and the heavy chain CDR3 sequence of

247 mAb 4E4.

VHeavy 1-2 IGHV1-2	FR1 (11-26) EVKKPGASVKVSCKAS	CDR1 (27-38) GYTFTGYY	FR2 (39-55) MHWVROAPGOGLEWMGR	CDR2 (56-65) INPNSGGT.	FR3 (66-104) NYAOKFO.GRVTMTRDTSISTAYMELSRLRSDDTAVYYC	. //	4E4 HCDR3 CARGEIAGRRLDLW
1B1 (02)			II	VK-SDA	D-RSTDSFL-F-		S-TA-WP-
(12-)							
1F7 (Q2)			I	-KD-	DRETNEL		STTT-WP-
6f11 (Q7)	-LRLRI-	S	I	-SSTA-	-FRSLN-M-LRG-TS		-G-TSS-HS-
7C6 (Q7)	-L-NVRQL-	S-F-	IIR-H	-SSTAA.	TSRLSN-F-L-VKG-TFS-I-F-		-G-TSS-HS-
6F5 (Q13)	RR	ISA-S	I	-T-SA-	VIATT-G-LNLI		VQMDA
4E4 (Q11)	R	MIA	V	-KA	DG-SND-TG-T		
					shared HCDR3 amino ac	ids	** ***
76Canc^					shared HCDR3 amino ac		* * * * * *
76Canc^							* * * * * *
		 CDR1 (27-38)		 CDR2 (56-65)			6F5 KCDR3
VKappa 1-3		CDR1 (27-38)					
76Canc [^] VKappa 1-3 IGKV1-39. 6f11 (Q7)	9 FR1(9-26)	CDR1 (27-38) S QSI.SSY) FR2 (39-55)	CDR2 (56-65) AA.S	 FR3 (66-104)		6F5 KCDR3
VKappa 1-3 IGKV1-39. 6f11 (Q7)	9 FR1 (9-26) SSLSASVGDRVTITCRA:	CDR1 (27-38) S QSI.SSY G -NAK-) FR2(39-55) LNWYQQKPGKAPKLLIY	CDR2 (56-65) AA.S D	FR3(66-104) SLQSGVP.SRFSGSG.SGTDFTLTISSLQPEDFATYY		6F5 KCDR3 CQQTYASPPWTF ESV
VKappa 1-3 IGKV1-39. 6f11 (Q7) 7c6 (Q7)	9 FR1 (9-26) SSLSASVGDRVTITCRA: -A(CDR1 (27-38) S QSI.SSY G -NAK- G -NGKF) FR2(39-55) LNWYQQKPGKAPKLLIY -HSH	CDR2 (56-65) AA.S D D	FR3(66-104) SLQSGVP.SRFSGSG.SGTDFTLTISSLQPEDFATYY DVN		6F5 KCDR3 CQQTYASPPWTF
VKappa 1-3 IGKV1-39. 6f11 (Q7) 7c6 (Q7)	9 FR1(9-26) SSLSASVGDRVTITCRA: -A(CDR1 (27-38) S QSI.SSY G -NAK- G -NGKF TTF	FR2 (39-55) LNWYQQKPGKAPKLLIY -HSH -HSSH	CDR2 (56-65) AA.S D D	FR3(66-104) SLQSGVP.SRFSGSG.SGTDFTLTISSLQPEDFATYY D		6F5 KCDR3 CQQTYASPPWTF ESV ESV

Figure 3: Sequence comparison of group 76C Abs supports that germline VH1-02 can contribute to epitope recognition. Comparison of the group 76C Abs (original clonal assignment by genetic relationship is shown; Q#, see methods) shows no mutations from germline shared in all clones. Despite the shared length, there are few shared amino acids in the CDR3 regions (*). Germline 4E4 HCDR3 contributed to the final 76anc construct. Gaps in IMGT numbering system are shown (.). Amino acids shared with predicted germline sequence are noted by dashes (-) and mutations away from germline are noted by their predicted single amino acid designation. ^76Canc heavy chain and 6F5 light chain was used in the recombinant 76Canc antibody.

248 **Ab 6F5 competition**

It is made available under a CC-BY 4.0 International license .

249 We initially compared HIV antigen binding of 76Canc to 6F5, 76A-2C6, and negative 250 control 8B10. 76Canc showed specific recognition of BaL trimers (Figure 4A) and gp41 clade 251 B protein (Figure 4B), but this was less than both 6F5 and 6F11. Results from 6F11, 76A-2C6 252 and 6F5 had comparable EC50 estimates to those previously published (Hicar, Chen, Sulli, et 253 al., 2016), as 76A-2C6 has a notably increased specificity for trimeric forms of envelope. From 254 gp41 binding, the estimated EC50 of 76Canc was 113.6 (ng/ml). To confirm antigen targeting 255 of 76Canc we performed competition ELISA using biotinylated 6F5 (6F5-biotin) recombinant 256 Ab with Trimer (Figure 4C) as well as gp41 (Figure 4D). 76Canc partially competed with 6F5-

257





Figure 4: Binding of representative group 76C Abs and competition against biotinylated 6F5. ELISA binding of representative group 76C Abs to A) trimer, and B) gp41 with 76A-2C6 as positive control and 8B10 as negative control. Competition of biotinylated 6F5 antibody with group 76C Abs on C) trimer and D) gp41. Blank signifies no competitive Ab addition. Experiments were repeated thrice with representative results of single experiment shown.

It is made available under a CC-BY 4.0 International license .

267 Post fusion six helix bundle (6HB) binding

268	Our earlier study (Hicar, Chen, Sulli, et al., 2016) showed
269	mutations widely separated on the primary sequence (R557,
270	E654 and E657; numbering per HXB2 reference sequence)
271	affected 6F5 binding. To confirm these Abs can target the post-
272	fusion forms of gp41, we used peptides previously described
273	that can replicate this post-fusion form. The two peptides N36
274	(SGIVQQQNNLLRAIEAQQHLLQLTVWGIKQLQARI) and C34
275	(WMEWDREINNYTSLIHSLIEESQNQQEKNEQELL), each
276	containing one of the heptad repeats, can form the post-fusion
277	6HB in vitro, which can be visualized by gel shift (Liu et al.,
278	2003). On native gel PAGE (Figure 5A), the N36 peptide is not
279	shown as it's higher pl of 11.2, prevented it from entering the
280	gel. With mixing prior to gel loading of the C34 peptide (acidic pl
281	of 3.4) with N36, an appreciable shift is noted compared to C34
282	lane alone (Figure 5A). The 6HB formation was confirmed by
283	probing with NC-1 Ab (Figure 5B); an Ab specific to the post-
284	fusion form as shown by lack of binding to C34 alone (Jiang,



Log 10 ng/mL

- 285 Lin, & Lu). On sandwich ELISA testing
- 286 using NC-1 as a capture Ab, 6F11,
- 6F5, and 76Canc all bound the 6HB 287
- 288 comparable to HK20, an Ab that
- 289 targets the 6HB. Further, a 6HB

Figure 5: Six-helix-bundle (6HB) formation and binding of various Abs.

10


A) Coomassie blue staining of C34 & 6HB formed by incubating N36 and C34. B) Western blot of C34 & 6HB with anti-mouse NC1 monoclonal Ab. C) 6HB sandwich ELISA binding using capture Ab NC1. D) Western blot analysis of 6HB binding of various Abs using decaprobe. E) 6HB binding competition against biotinylated 6F5 Ab. Experiments were repeated at least twice with representative results from single experiments shown.

It is made available under a CC-BY 4.0 International license .

- 290 specific interaction was confirmed using western blot and decaprobe by running 6HB
- 291 preparative gel on charge basis (Figure 5D). 6HB binding of these group 76 Abs was further
- confirmed by competition with 6F5-biotin (Figure 5E). Again, the 76Canc partially competes
- with 6F5 binding, where 6F11 and 6F5 more efficiently compete.
- 294

295 Functional activity of Germline based 76Canc

Because 76Canc competed with 6F5 and targeted the 6HB similarly to 6F5 and 6F11, we then assessed its ADCC function. 76Canc was surprisingly comparable in activity to 6F5 and 6F11 against both clad B and C targets (**Figure 6**). despite having relatively lower EC50 (**Figure 4**) and no mutations away from predicted germline heavy chain outside of the CDR3 region (**Figure 3**).



301

302

It is made available under a CC-BY 4.0 International license .

304 **Discussion**

305 Elicitation of broadly neutralizing Abs remains a goal of HIV vaccine research. While 306 these Abs can arise during HIV-1 infection, our limited knowledge of their germline, pre-307 immune Ab responses limits our ability to elicit them through vaccination (Yacoob et al., 2016). 308 We show here that an Ab with germline VH1-02 can recognize and show appreciable ADCC 309 activity against HIV. This ADCC activity with germline variable segment contributions, the 310 diversity of these mature clones, and the initial cross-reactive binding studies shown here 311 support that these Abs were formed from naïve B cell responses. This finding has direct 312 implications on current vaccine regimens. Identification of epitopes that can be recognized by 313 germline antibodies with functional activity may allow for a more direct route for vaccination 314 (single antigen and/or low number of booster approach) (Stamatatos, Pancera, & McGuire, 315 2017) rather than complicated multiple boosting regimens with variable antigens (Saunders et 316 al., 2019).

317 Highly mutated anti-CD4bs bnAbs preferentially use the VH1 gene, in particular the VH 318 1-02 and 1-46 segments, as the heavy chain predominantly drives CD4 binding site 319 recognition (Scheid et al., 2011; Wu et al., 2010). VRC01 is highly mutated, with V-gene region 320 amino acid predicted mutations of 42% in the VH1-02 heavy chain and 28% in the light chain 321 (Wu et al., 2010; Zhou et al., 2010). There is structural convergence of VRC01 related Abs and 322 these rely on short CDRs in chosen light chains (Zhou et al., 2010; Zhou et al., 2013). In 323 contrast to 76Canc, unmutated common ancestors of VRC01 Abs don't interact with native 324 trimers(Hoot et al., 2013). This potentially could interfere with vaccination strategies based on 325 the concept of stimulating the naïve Ab to generate a HIV bnAb response (Hoot et al., 2013; 326 McGuire et al., 2013; Zhou et al., 2010). Select framework mutations in VRC01 to 'near'

It is made available under a CC-BY 4.0 International license .

germline did maintain functionality (Georgiev et al., 2014). Recently, recombinant humanized
immunoglobulin mouse models using VH1-02 sequences and a sequential immunization
strategy have shown success in creating similarly matured Abs (Tian et al., 2016). Potentially
these strategies can be utilized to similarly target 76C-like Abs.

331 As the members of 76C showed general structural homology, but few shared mutations, 332 76C-like Abs may arise from a truly naïve initial response. However, Abs with low numbers of 333 mutations may have been originally focused on other antigens. A number of the HIV bnAbs 334 have been described as having autoimmune potential (Zandman-Goddard & Shoenfeld, 2002). 335 As prior studies have suggested, gp41 targeting during initial infection relies predominantly on 336 stimulating memory B cells that have previously been activated by non-HIV-1 antigens. A 337 similar study with germline reversion of gp41 targeting Abs has been performed; however, 338 germline Abs lacked HIV reactivity (Liao et al., 2011). These Abs were found to be poly-339 reactive and bound to various host or gut flora antigens. A number of gut ileum B cell derived 340 anti-gp41 Abs cross-reacted to commensal bacteria and showed non-HIV-1 polyreactivity 341 (Trama et al.). Groups have postulated that germline Abs primed by reactions to commensal 342 bacteria can be stimulated and form the basis for anti-gp41 Ab responses after infection. 343 The original antigen that was recognized by these clones remains unknown. We show

that the 76Canc binds the 6HB comparable to other 76C Abs, but is less efficient at competing against 6F5. It may be that a structure similar to the 6HB was the original selective antigen.
Since these Abs were cloned from LTNPs and similar Abs are more prevalent in LTNPs, it is intriguing to consider that the potential effects of this type of functional Ab response early in an infection could influence the global clinical course of disease.

349

It is made available under a CC-BY 4.0 International license .

350 **Conclusions**:

Here we show that the VH1-02 germline variable chain can support ADCC. Exploring the targeting of ancestor Abs such as this may help inform on future vaccine efforts. The shepherding of a naïve response all the way to highly mutated Abs remains a challenge. Targeting efforts to expand functional Abs utilizing germline sequences, such as 76Canc, may offer a simpler path to immune protection or assist in immunity during vaccination with more complex regimens.

357

358 Acknowledgements:

359 We thank Dr. Julie Overbaugh for her comments on previous versions of this 360 manuscript. We thank Dr. J Bloom for providing influenza- specific monoclonal Ab F16V3. The 361 following reagents were obtained through the AIDS Research and Reference Reagent 362 Program, Division of AIDS, NIAID, NIH: monoclonal Abs 2G12 from Dr. Hermann Katinger; 363 anti-HIV-1 gp41 monoclonal Ab NC-1 from Dr. Shibo Jiang. This research was supported 364 through biorepository access by Research reported in this [publication/press release] was 365 supported by the University of Washington / Fred Hutch Center for AIDS Research, an NIH-366 funded program under award number AI027757 which is supported by the following NIH 367 Institutes and Centers: NIAID, NCI, NIMH, NIDA, NICHD, NHLBI, NIA, NIGMS, NIDDK. Study 368 was supported by NIH R01 AI 125119-01; "The role of non-broadly neutralizing antibodies 369 targeting gp41 structural epitopes in long term nonprogression of HIV infection."

370

371 **Competing Interests:**

372 All authors declare no competing interests.

It is made available under a CC-BY 4.0 International license .

373 **References**:

- Bonsignori, M., Pollara, J., Moody, M. A., Alpert, M. D., Chen, X., Hwang, K. K., . . . Haynes, B. F. (2012).
 Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy
 trial target multiple epitopes and preferentially use the VH1 gene family. *J Virol, 86*(21), 11521 11532. doi:10.1128/JVI.01023-12
- Burton, D. R., Hessell, A. J., Keele, B. F., Klasse, P. J., Ketas, T. A., Moldt, B., . . . Moore, J. P. (2011).
 Limited or no protection by weakly or nonneutralizing antibodies against vaginal SHIV challenge
 of macaques compared with a strongly neutralizing antibody. *Proc Natl Acad Sci U S A, 108*(27),
 11181-11186. doi:10.1073/pnas.1103012108
- Das, J., Devadhasan, A., Linde, C., Broge, T., Sassic, J., Mangano, M., . . . Alter, G. (2020). Mining for
 humoral correlates of HIV control and latent reservoir size. *PLoS Pathog*, *16*(10), e1008868.
 doi:10.1371/journal.ppat.1008868
- Georgiev, I. S., Rudicell, R. S., Saunders, K. O., Shi, W., Kirys, T., McKee, K., . . . Kwong, P. D. (2014).
 Antibodies VRC01 and 10E8 neutralize HIV-1 with high breadth and potency even with Ig framework regions substantially reverted to germline. *J Immunol, 192*(3), 1100-1106.
 doi:10.4049/jimmunol.1302515
- Haynes, B. F., Gilbert, P. B., McElrath, M. J., Zolla-Pazner, S., Tomaras, G. D., Alam, S. M., . . . Kim, J. H.
 (2012). Immune-correlates analysis of an HIV-1 vaccine efficacy trial. *N Engl J Med*, *366*(14),
 1275-1286. doi:10.1056/NEJMoa1113425
- Hessell, A. J., Hangartner, L., Hunter, M., Havenith, C. E., Beurskens, F. J., Bakker, J. M., . . . Burton, D. R.
 (2007). Fc receptor but not complement binding is important in antibody protection against
 HIV. *Nature*, 449(7158), 101-104. doi:10.1038/nature06106
- Hessell, A. J., Rakasz, E. G., Tehrani, D. M., Huber, M., Weisgrau, K. L., Landucci, G., . . . Burton, D. R.
 (2009). Broadly Neutralizing Monoclonal Antibodies 2F5 and 4E10, Directed Against the Human
 Immunodeficiency Virus Type 1 (HIV-1) gp41 Membrane Proximal External Region (MPER),
 Protect Against SHIVBa-L Mucosal Challenge. *J Virol*. doi:JVI.01272-09 [pii]
- 399 10.1128/JVI.01272-09
- Hicar, M. D., Chen, X., Kalams, S. A., Sojar, H., Landucci, G., Forthal, D. N., . . . Crowe, J. E., Jr. (2016).
 Low frequency of broadly neutralizing HIV antibodies during chronic infection even in
 quaternary epitope targeting antibodies containing large numbers of somatic mutations. *Mol Immunol, 70*, 94-103. doi:10.1016/j.molimm.2015.12.002
- Hicar, M. D., Chen, X., Sulli, C., Barnes, T., Goodman, J., Sojar, H., . . . Crowe, J. E., Jr. (2016). Human
 Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env
 Protein. *PLoS One, 11*(7), e0158861. doi:10.1371/journal.pone.0158861
- Hoot, S., McGuire, A. T., Cohen, K. W., Strong, R. K., Hangartner, L., Klein, F., . . . Stamatatos, L. (2013).
 Recombinant HIV envelope proteins fail to engage germline versions of anti-CD4bs bNAbs. *PLoS Pathog*, 9(1), e1003106. doi:10.1371/journal.ppat.1003106
- Jiang, S., Lin, K., & Lu, M. (1998). A conformation-specific monoclonal antibody reacting with fusionactive gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. *J Virol*,
 72(12), 10213-10217.

Lambotte, O., Ferrari, G., Moog, C., Yates, N. L., Liao, H. X., Parks, R. J., . . . Delfraissy, J. F. (2009). Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. *AIDS*, 23(8), 897-906. doi:10.1097/QAD.0b013e328329f97d

416 Liao, H. X., Chen, X., Munshaw, S., Zhang, R., Marshall, D. J., Vandergrift, N., . . . Haynes, B. F. (2011). 417 Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly 418 mutated. J Exp Med, 208(11), 2237-2249. doi:10.1084/jem.20110363 419 Liu, S., Zhao, Q., & Jiang, S. (2003). Determination of the HIV-1 gp41 fusogenic core conformation 420 modeled by synthetic peptides: applicable for identification of HIV-1 fusion inhibitors. Peptides, 421 24(9), 1303-1313. doi:10.1016/j.peptides.2003.07.013 422 McGuire, A. T., Hoot, S., Dreyer, A. M., Lippy, A., Stuart, A., Cohen, K. W., . . . Stamatatos, L. (2013). Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing 423 424 anti-CD4 binding site antibodies. J Exp Med, 210(4), 655-663. doi:10.1084/jem.20122824 425 Milligan, C., Richardson, B. A., John-Stewart, G., Nduati, R., & Overbaugh, J. (2015). Passively acquired 426 antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated 427 with reduced mortality. Cell Host Microbe, 17(4), 500-506. doi:10.1016/j.chom.2015.03.002 428 Parren, P. W., Ditzel, H. J., Gulizia, R. J., Binley, J. M., Barbas, C. F., 3rd, Burton, D. R., & Mosier, D. E. 429 (1995). Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a 430 neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS, 9(6), F1-6. 431 Parren, P. W., Fisicaro, P., Labrijn, A. F., Binley, J. M., Yang, W. P., Ditzel, H. J., . . . Burton, D. R. (1996). 432 In vitro antigen challenge of human antibody libraries for vaccine evaluation: the human 433 immunodeficiency virus type 1 envelope. J Virol, 70(12), 9046-9050. 434 Santra, S., Tomaras, G. D., Warrier, R., Nicely, N. I., Liao, H. X., Pollara, J., . . . Haynes, B. F. (2015). 435 Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder 436 Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathog, 11(8), e1005042. 437 doi:10.1371/journal.ppat.1005042 438 Saunders, K. O., Wiehe, K., Tian, M., Acharya, P., Bradley, T., Alam, S. M., . . . Haynes, B. F. (2019). 439 Targeted selection of HIV-specific antibody mutations by engineering B cell maturation. Science, 440 366(6470). doi:10.1126/science.aay7199 441 Scheid, J. F., Mouquet, H., Ueberheide, B., Diskin, R., Klein, F., Oliveira, T. Y., . . . Nussenzweig, M. C. 442 (2011). Sequence and structural convergence of broad and potent HIV antibodies that mimic 443 CD4 binding. Science, 333(6049), 1633-1637. doi:10.1126/science.1207227 444 Smith, M., Hoffman, J., Sojar, H., Aalinkeel, R., Hsiao, C. B., & Hicar, M. D. (2018). Assessment of 445 Antibody Interference of Enfuvirtide (T20) Function Shows Assay Dependent Variability. Curr 446 *HIV Res, 16*(6), 404-415. doi:10.2174/1570162X17666190228154850 447 Sojar, H., Baron, S., Sullivan, J. T., Garrett, M., van Haaren, M. M., Hoffman, J., . . . Hicar, M. D. (2019). 448 Monoclonal Antibody 2C6 Targets a Cross-Clade Conformational Epitope in gp41 with Highly 449 Active Antibody-Dependent Cell Cytotoxicity. J Virol, 93(17). doi:10.1128/JVI.00772-19 450 Stamatatos, L., Pancera, M., & McGuire, A. T. (2017). Germline-targeting immunogens. Immunol Rev, 451 275(1), 203-216. doi:10.1111/imr.12483 452 Tian, M., Cheng, C., Chen, X., Duan, H., Cheng, H. L., Dao, M., . . . Alt, F. W. (2016). Induction of HIV 453 Neutralizing Antibody Lineages in Mice with Diverse Precursor Repertoires. Cell, 166(6), 1471-1484 e1418. doi:10.1016/j.cell.2016.07.029 454 455 Trama, Ashley M., Moody, M. Anthony, Alam, S. Munir, Jaeger, Frederick H., Lockwood, Bradley, Parks, 456 Robert, . . . Haynes, Barton F. (2014). HIV-1 envelope gp41 antibodies can originate from 457 terminal ileum B cells that share cross-reactivity with commensal bacteria. Cell host & microbe, 458 16(2), 215-226.

459 460 461 462 463 464 465	 Williams, K. L., Cortez, V., Dingens, A. S., Gach, J. S., Rainwater, S., Weis, J. F., Overbaugh, J. (2015). HIV-specific CD4-induced Antibodies Mediate Broad and Potent Antibody-dependent Cellular Cytotoxicity Activity and Are Commonly Detected in Plasma From HIV-infected humans. <i>EBioMedicine</i>, 2(10), 1464-1477. doi:10.1016/j.ebiom.2015.09.001 Wu, X., Yang, Z. Y., Li, Y., Hogerkorp, C. M., Schief, W. R., Seaman, M. S., Mascola, J. R. (2010). Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. <i>Science</i>, 329(5993), 856-861. doi:10.1126/science.1187659
466	Yacoob, C., Pancera, M., Vigdorovich, V., Oliver, B. G., Glenn, J. A., Feng, J., Stamatatos, L. (2016).
467	Differences in Allelic Frequency and CDRH3 Region Limit the Engagement of HIV Env
468	Immunogens by Putative VRC01 Neutralizing Antibody Precursors. Cell Rep, 17(6), 1560-1570.
469	doi:10.1016/j.celrep.2016.10.017
470	Zandman-Goddard, G., & Shoenfeld, Y. (2002). HIV and autoimmunity. <i>Autoimmun Rev, 1</i> (6), 329-337.
471	doi:10.1016/s1568-9972(02)00086-1
472	Zhou, T., Georgiev, I., Wu, X., Yang, Z. Y., Dai, K., Finzi, A., Kwong, P. D. (2010). Structural basis for
473	broad and potent neutralization of HIV-1 by antibody VRC01. Science, 329(5993), 811-817.
474	doi:10.1126/science.1192819
475	Zhou, T., Zhu, J., Wu, X., Moquin, S., Zhang, B., Acharya, P., Kwong, P. D. (2013). Multidonor analysis
476	reveals structural elements, genetic determinants, and maturation pathway for HIV-1
477	neutralization by VRC01-class antibodies. <i>Immunity, 39</i> (2), 245-258.
478	doi:10.1016/j.immuni.2013.04.012
479	